

WEST Search History

DATE: Friday, May 24, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L29	L3 and L4	1	L29
L28	L3 and L22	173	L28
L27	L26 and L7	94	L27
L26	L25 and L24	383	L26
L25	potentiate	8130	L25
L24	L16 and L22	5122	L24
L23	l16 AND l21	3668	L23
L22	side and effects	1088137	L22
L21	side effects	80113	L21
L20	L3 and L16 and L7	20	L20
L19	L3 and L16	92	L19
L18	L1 and L16	7	L18
L17	L16 L1 and L3	0	L17
L16	prodrug	11808	L16
L15	L13 and L7	42	L15
L14	L1 and L3 and L7 and L13	0	L14
L13	irinotecan	247	L13
L12	irinofecan	0	L12
L11	L1 and L2	4	L11
L10	L1 and L6 and L7 and L8	0	L10
L9	L1 and L2 and L3 and L4	0	L9
L8	anti-sense	5376	L8
L7	antisense	20799	L7
L6	oligonucleotide	42171	L6
L5	polysulfate	927	L5
L4	polyanion	3760	L4
L3	CPT-11	269	L3
L2	SN-38	64	L2
L1	camptosar	18	L1

END OF SEARCH HISTORY

4. 20020041898. 25 Jul 01. 11 Apr 02. Novel
targeted delivery systems for bioactive agents. Unger,
Evan C., et al. 424/486; 424/178.1 A61K009/14
A61K039/395.
DOCUMENT-IDENTIFIER: US 20020041898 A1
TITLE: Novel targeted delivery systems for bioactive agents

Detail Description Paragraph (43):

[0063] The length of the polypeptide as well as the particular amino acids employed may be selected, for example, to optimize the interaction between the polypeptide and the bioactive agent including, for example, the extent and the manner in which the polypeptide may envelop, fold or wrap around the bioactive agent. For example, in the case of polyleucine, other amino acids, such as, for example, glycine or proline, may be incorporated into the polypeptide to modify the way the polypeptide bends which may permit increased and more efficient wrapping of the polypeptide around the bioactive agent. Similarly, domains of amino acids may be selected and incorporated in the polypeptide which may improve the chemical interaction or association with the bioactive agent. For example, **the drug irinotecan is a lipophilic cation, and the drug camptothecin is hydrophobic although the pyridine residue may be attached to the 10-hydroxy position of camptothecin to provide a pro-drug.** The pyridine moiety may also carry a positive charge at physiological pH from the quaternary amine. Incorporating one or more anionic amino acids, for example, glutamate, into the polyleucine polypeptide, may serve to increase the interaction of the predominantly polyleucine polypeptide with camptothecin. **In general, for bioactive agents such as irinotecan, which are lipophilic cations, incorporating an anionic segment into the polypeptide may increase the interaction.** Conversely, for bioactive agents that are lipophilic anions, one or more cationic amino acids, for example, lysine, arginine or histidine, may be incorporated into the polypeptide. Without intending to be bound by any theory or theories of operation, it is contemplated that the polypeptide may serve as a hydrophobic block which facilitates hydrogen bonding with a bioactive agent containing a charged domain, thereby enabling the formation of a complex, or some other interaction, for example, ion pairing of the polypeptide with the polar, charged portion of the bioactive agent.

Detail Description Paragraph (134):

[0153] anticancer agents, including antineoplastic

agents--paclitaxel, docetaxel, camptothecin and its analogues and derivatives (e.g., 9-aminocamptothecin, 9-nitrocamptothecin, 10-hydroxy-camptothecin, irinotecan, topotecan, 20-O-glucopyranosyl camptothecin), taxanes (baccatins, cephalomannine and their derivatives), carboplatin, cisplatin, interferon-2A, interferon-2B, interferon-N3 and other agents of the interferon family, levamisole, altretamine, cladribine, bovine-calmette-guerin (BCG), aldesleukin, tretinoin, procarbazine, dacarbazine, gemcitabine, mitotane, asparaginase, porfimer, mesna, amifostine, mitotic inhibitors including podophyllotoxin derivatives such as teniposide and etoposide and vinca alkaloids such as vinorelbine, vincristine and vinblastine;

Detail Description Paragraph (155):

[0174] topoimerase inhibitors--camptothecin, anthraquinones, anthracyclines, temiposide, etoposide, topotecan and irinotecan.

Detail Description Paragraph (157):

[0176] In addition to the foregoing bioactive agents, the present compositions may be useful as delivery vehicles for genetic material, e.g., a nucleic acid, RNA, DNA, recombinant RNA, recombinant DNA, antisense RNA, antisense DNA, hammerhead RNA, a ribozyme, a hammerhead ribozyme, an antigene nucleic acid, a ribo-oligonucleotide, a deoxyribonucleotide, an antisense ribo-oligonucleotide, and an antisense deoxyribo-oligonucleotide. Representative genes include, for example, those which code growth factors and other proteins such as vascular endothelial growth factor, fibroblast growth factor, BCL-2, cystic fibrosis transmembrane regulator, nerve growth factor, human growth factor, erythropoietin, tumor necrosis factor, and interleukin-2, histocompatibility genes such as HLA-B7, genes coding for enzymes regulating metabolism such as glycolytic enzymes, enzymes of the citric acid cycles and oxidative phosphorylation, genes for hormones such as insulin, glucagon and vasopressin, oncogenes and protooncogenes such as c-fos and c-jun, tumor supression factors such as p53 and telomeres. The genes employed in the compositions may be in the form of gene therapy vectors including, for example, virus-based vectors derived from Adenovirus, adeno-associated virus (AAV), lentiviruses (i.e., retroviruses, such as HIV), herpes simplex virus and, to some extent, vaccinia virus.

6. 20020035090. 14 May 01. 21 Mar 02.

Compositions and methods for the treatment of

cancer. Zeldis, Jerome B., et al. 514/58; 514/211.08
514/283 514/291 514/43 A61K031/724
A61K031/7056 A61K031/4745.

Summary of Invention Paragraph (25):

[0025] A specific camptothecin analogue is irinotecan (also referred to as CPT-11), which is chemically named (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino)carbonyloxy]-1H-pyranol-[3',4':6,7]indolizino[1,2-b]quinoxaline-3,14-(4H,12H)dione and is described in U.S. Pat. No. 4,604,463. **The hydrochloride trihydrate** of irinotecan is sold under the tradename **CAMPTOSAR**.RTM., and is indicated in the United States for the treatment of patients with metastatic carcinoma of the colon or rectum that recurred or progressed following 5-fluorouracil based therapy. Physicians' Desk Reference, 2412-2418 (54.sup.th ed., 2000). It has also recently been approved in the United States as a first-line therapy to treat patients with metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin. Irinotecan has also reportedly been used to treat other cancers, such as malignant gliomas and NSCLC. See, e.g., Avgeropoulos, N. G., and Batchelor, T. T., The Oncologist 4:209-224 (1999).

1. 20020055666. 24 May 01. 09 May 02.

Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors. Hunter, William L., et al. 600/1; 604/27 A61N005/00.

Detail Description Paragraph (117):

[0169] Within one aspect of the invention, ribozymes or antisense sequences (as well as gene therapy vehicles which can deliver such sequences) can be utilized as cell cycle inhibitors. One representative example of such inhibitors is disclosed in PCT Publication No. WO 00/32765 (which, as noted above, is incorporated by reference in its entirety).

4. 20020049217. 09 Jan 01. 25 Apr 02.

Inhibitors of prenyl-protein transferase. deSolms, S. Jane, et al. 514/257; 514/183 514/397 514/9540/454 A61K038/00 A61K031/505 A61K031/415.

DOCUMENT-IDENTIFIER: US 20020049217 A1

TITLE: Inhibitors of prenyl-protein transferase

Summary of Invention Paragraph (758):

[0759] Example classes of antineoplastic agents include, for

example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the taxanes, the epothilones, discodermolide, the pteridine family of drugs, diylenes and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, tamoxifen, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), procarbazine, mitomycin, cytarabine, etoposide, methotrexate, bleomycin, chlorambucil, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole of antineoplastic, or chemotherapeutic, agents are described, for example, by D. J. Stewart in "Nausea and Vomiting: Recent Research and Clinical Advances", Eds. J. Kucharczyk, et al., CRC Press Inc., Boca Raton, Fla., USA (1991), pages 177-203, especially page 188. See also, R. J. Gralla, et al., Cancer Treatment Reports, 68(1), 163-172 (1984).

Summary of Invention Paragraph (760):

[0761] The compounds of the instant invention may also be co-administered with **antisense oligonucleotides** which are specifically hybridizable with RNA or DNA deriving from human **ras gene**. Such antisense oligonucleotides are described in U.S. Pat. No. 5,576,208 and PCT Publ. No. WO 99/22772. The instant compounds are particularly useful when co-administered with the antisense oligonucleotide comprising the amino acid sequence of SEQ.ID.NO: 2 of U.S. Pat. No. 5,576,208.

20020035090. 14 May 01. 21 Mar 02.

Compositions and methods for the treatment of cancer. Zeldis, Jerome B., et al. 514/58; 514/211.08 514/283 514/291 514/43 A61K031/724 A61K031/7056 A61K031/4745.

Summary of Invention Paragraph (25):

[0025] A specific camptothecin analogue is irinotecan (also referred to as CPT-11), which is chemically named (4S)-4,11

-diethyl-4-hydroxy-9-[(4-piperidino)carbonyl-oxy]1H-pyranol-[3',4':6,7]indolizino[1,2-b]quinoxaline-3,14-(4H,12H)dione and is described in U.S. Pat. No. 4,604,463. The hydrochloride trihydrate of irinotecan is sold under the tradename CAMPTOSAR.RTM., and is indicated in the United States for the treatment of patients with metastatic carcinoma of the colon or rectum that recurred or progressed following 5-fluorouracil based therapy. Physicians' Desk Reference, 2412-2418 (54.sup.th ed., 2000). It has also recently been approved in the United States as a first-line therapy to treat patients with metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin. Irinotecan has also reportedly been used to treat other cancers, such as malignant gliomas and NSCLC. See, e.g., Avgeropoulos, N. G., and Batchelor, T. T., The Oncologist 4:209-224 (1999).

Summary of Invention Paragraph (70):

[0070] Examples of anti-cancer drugs that can be used in the various embodiments of the invention, including pharmaceutical compositions and dosage forms and kits of the invention, include, but are not limited to ; **antisense oligonucleotides**

19. 6077499. 03 Nov 98; 20 Jun 00. Targeted combination immunotherapy of cancer. Griffiths; Gary L., et al. 424/1.49; 424/1.11 424/1.65. A61K051/00 A61M036/14.

CLAIMS:

1. A composition for effecting therapy of a tumor in a patient, comprising:

(A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor;

(B) optionally, a clearing agent; and

(C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent,

wherein the binding pair is selected from the group consisting of (a) complementary DNA fragments, (b) complementary peptide oligonucleotides, and (c) corresponding enzymes and prodrug

substrates.

29. The composition of claim 1, wherein the first member of the binding pair of the first conjugate comprises an enzyme and the second conjugate comprises a prodrug which is converted to a drug by the enzyme, wherein the prodrug comprises both the complementary member of the binding pair and the second therapeutic agent.

30. The composition of claim 29 wherein said second therapeutic agent is the same as or different from said first therapeutic agent, wherein said enzyme is carboxypeptidase G2 and said prodrug is CPT-11.

0. 5786344. 17 Apr 95; 28 Jul 98.

Camptothecin drug combinations and methods with reduced side effects. Ratain; Mark J., et al. 514/100; 424/143.1 514/171 514/183 514/211.07 514/211.08 514/28 514/9. A61K031/545 A61K031/47.

Brief Summary Paragraph Right (36):

As the present invention provides for increasing the amount of a conjugative enzyme, such as glucuronosyltransferase, and decreasing the amount of a transporter, such as p-glycoprotein, useful "second agents" also include recombinant vectors and constructs. For example, administering a recombinant form of a glucuronosyltransferase enzyme, or an antisense DNA construct that is complementary to p-glycoprotein transporter nucleic acid sequences, is envisioned. Second agent recombinant vectors are those that comprise a sequence region encoding a conjugative enzyme or an antisense version of a biliary transport protein, where the vectors are capable of expressing the sequence region in the type of mammalian that is to be treated.

Other Reference Publication (9):

Zhu, G., et al., "The effect of vincristine-polyanion complexes in Stealth liposomes on pharmacokinetics, toxicity and anti tumor activity" Cancer Chemother Pharmacol 39:138-142 (1996).